We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 15, 2017

Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer: MONARCH 2

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
J. Clin. Oncol 2017 Jun 03;[EPub Ahead of Print], GW Sledge, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, M Okera, N Masuda, PA Kaufman, H Koh, EM Grischke, M Frenzel, Y Lin, S Barriga, IC Smith, N Bourayou, A Llombart-Cussac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading